Gastrointestinal Bleeding News and Research

RSS

Gastrointestinal bleeding or gastrointestinal hemorrhage describes every form of hemorrhage (loss of blood) in the gastrointestinal tract, from the pharynx to the rectum.

Physicians beware of fruity drug interactions

An understanding of the potential for pharmacokinetic interaction between orally administered drugs and grapefruit is necessary in view of an increase in marketed medications that fit the risk criteria, suggest Canadian researchers.

30 Nov 2012

Pradaxa use does not appear to increase serious bleeding

The U.S. Food and Drug Administration (FDA) today announced the results of a Mini-Sentinel assessment that indicates bleeding rates associated with new use of Pradaxa (dabigatran etexilate mesylate) capsules do not appear to be higher than bleeding rates associated with new use of warfarin, which is consistent with observations from the pivotal RE-LY trial.

4 Nov 2012

Aspirin can block tumor growth in certain patients with colorectal cancer

Aspirin has the potential to block tumor growth in certain patients with colorectal cancer, according to an editorial in the Oct. 25, 2012 issue of the New England Journal of Medicine by a University of Alabama at Birmingham oncologist.

25 Oct 2012

Study finds decline in inpatient mortality rate for upper gastrointestinal hemorrhage in the U.S.

The number of patients dying from upper gastrointestinal bleeding has decreased over the past two decades, a result researchers attribute to the advances in medical and endoscopic therapies introduced over the past 20 years, according to a report unveiled today at the American College of Gastroenterology's (ACG) 77th Annual Scientific meeting in Las Vegas.

24 Oct 2012

Phase 3 study of INLYTA fails to meet primary endpoint in treatment-naïve patients with RCC

Pfizer Inc. announced today that a Phase 3 study of INLYTA (axitinib) did not meet its primary endpoint of demonstrating statistically significantly longer progression-free survival, versus sorafenib, in treatment-naïve patients with advanced renal cell carcinoma.

18 Oct 2012

Prognosis still poor for EVB in cirrhosis

The current standard of care for esophageal variceal bleeding in liver cirrhosis is very effective at controlling bleeding but patient prognosis remains poor, say the authors of an Italian study.

1 Oct 2012

Warfarin therapy should not be stopped completely after GI bleeding

The decision to not resume warfarin therapy following a gastrointestinal bleeding event is linked to an increased risk for thrombosis and mortality, researchers suggest.

27 Sep 2012

Warfarin therapy should not be stopped completely after GI bleeding

The decision to not resume warfarin therapy following a gastrointestinal bleeding event is linked to an increased risk for thrombosis and mortality, researchers suggest.

25 Sep 2012

FDA approves Novartis’ Exelon Patch to treat mild to moderate AD

The US Food and Drug Administration has approved a higher dose of Exelon Patch (rivastigmine transdermal system) for the treatment of people with mild to moderate Alzheimer's disease.

4 Sep 2012

Emergency readmission after endoscopy linked to mortality risk

The risk for mortality is significantly increased among patients who are readmitted urgently following endoscopy, compared with other endoscopy patients, a UK study shows.

30 Aug 2012

Sanofi-aventis receives FDA approval for Zaltrap to treat colorectal cancer

The U.S. Food and Drug Administration today approved Zaltrap (ziv-aflibercept) for use in combination with a FOLFIRI (folinic acid, fluorouracil and irinotecan) chemotherapy regimen to treat adults with colorectal cancer.

6 Aug 2012

Bayer, Onyx and Astellas announce results from Tarceva plus Nexavar Phase 3 trial on HCC

Bayer HealthCare Pharmaceuticals, Onyx Pharmaceuticals, Inc., and Astellas Pharma Inc. today announced that a Phase 3 trial evaluating the efficacy and safety of the addition of Tarceva (erlotinib) tablets to Nexavar (sorafenib) tablets did not improve overall survival for patients with unresectable hepatocellular carcinoma (HCC) vs. Nexavar alone.

23 Jul 2012

Proton pump inhibitors for clopidogrel patients ‘not so dangerous’

The interaction between proton pump inhibitors and clopidogrel is “clinically unimportant,” say researchers in the BMJ.

19 Jul 2012

Alcohol has toxic effect on critical care services

Alcohol may account for more than one in 10 emergency department admissions, a study from the UK suggests.

10 Jul 2012

Familial predisposition ‘modestly’ affects alcoholic liver disease risk

Environmental factors appear to be the main influence on the risk for alcoholic liver disease, say researchers who found little evidence for familial predisposition to the condition.

11 Jun 2012

Theramine may reduce chronic low back pain

Physician Therapeutics, Inc., a division of Targeted Medical Pharma, Inc., a specialty pharmaceutical company that develops and distributes prescription medical foods to physicians, pharmacies and skilled nursing facilities, published results from a clinical trial of the company's proprietary medical food Theramine.

11 Jun 2012

Aspirin linked to high bleeding rate in diabetes

Diabetes may be associated with an increased risk for major bleeding irrespective of aspirin use, researchers say.

7 Jun 2012

How to manage conflicts of interest in guideline development remains unclear

Setting an ethics framework could be useful to identify and manage conflicts of interest in the context of developing clinical practice guidelines, suggest researchers.

7 Jun 2012

Sihuan's Roxatidine passes Chinese SFDA on-site inspection

Sihuan Pharmaceutical Holdings Group Ltd., a leading pharmaceutical company with the largest cardio-cerebral vascular drug franchise in China's prescription market, announced that Roxatidine Acetate Hydrochloride for Injection, Sihuan Pharmaceutical's first-to-market generic drug, recently passed on-site inspection for drug registration conducted by the Chinese State Food and Drug Administration.

25 May 2012

EMA CHMP adopts positive opinion for Pfizer’s axitinib to treat advanced renal cell carcinoma

Pfizer announced today that the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding the marketing authorization of axitinib in the European Union (EU), for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of advanced kidney cancer, after failure of prior treatment with sunitinib or a cytokine.

25 May 2012